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Abstract
Abnormally elevated hippocampal Caspase-6 (Casp6) activity is intimately associated with age-related cognitive
impairment in humans and in mice. In humans, these high levels of Casp6 activity are initially localized in the
entorhinal cortex, the area of the brain first affected by the formation of neurofibrillary tangles, according to Braak
staging. The reason for the high vulnerability of entorhinal cortex neurons to neurofibrillary tangle pathology and
Casp6 activity is unknown. Casp6 activity is involved in axonal degeneration, therefore, one possibility to explain
increased vulnerability of the entorhinal cortex neurons would be that the afferent neurons of the olfactory bulb,
some of which project their axons to the entorhinal cortex, are equally degenerating. To examine this possibility,
we examined the presence of Casp6 activity, neurofibrillary tangle formation and amyloid deposition by
immunohistochemistry with neoepitope antisera against the p20 subunit of active Casp6 and Tau cleaved by Casp6
(TauΔCasp6), phosphorylated Tau paired helical filament (PHF-1) antibodies and anti-β-amyloid antiserum,
respectively, in brains from individuals with no or mild cognitive impairment and Alzheimer disease (AD) dementia.
Co-localization of Casp6 activity, PHF-1 and β-amyloid was detected mostly in the anterior olfactory nucleus (AON)
of the olfactory bulb. The levels of active Casp6 in the AON, which were the highest in the AD brains, correlated
with PHF-1 levels, but not with β-amyloid levels. AON TauΔCasp6 levels correlated with entorhinal cortex Casp6
activity and PHF-1 levels. Multiple regression analyses demonstrated that AON Casp6 activity was associated with
lower global cognitive function, mini mental state exam, episodic memory and semantic memory scores. These
results suggest that AON Casp6 activity could lead to Casp6-mediated degeneration in the entorhinal cortex, but
cannot exclude the possibilities that entorhinal cortex degeneration signals degeneration in the AON or that the
pathologies occur in both regions independently. Nevertheless, AON Casp6 activity reflects that of the entorhinal
cortex.
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Introduction
Identification of specific early molecular mechanisms
underlying neurodegeneration and leading to age-related
cognitive impairment and AD dementia may provide
novel therapeutic targets against which efficient therapies
can be developed. Our laboratory has focused on Casp6, a
cytosolic cysteinyl protease, which is almost undetectable
in normal aged human brain tissues [25], but extremely
abundant and active in both sporadic [27] and familial [2]
AD. From early to late stages of AD, Casp6 activity is de-
tected in neurofibrillary tangles (NFT), neuritic plaques
and neuropil threads, the main pathological lesions of AD
[3, 27]. The activation of Casp6 in human primary neuron
cultures increases amyloid beta peptide production
[32, 36, 38]. Furthermore, Casp6 activity is implicated in
age-related cognitive impairment. In aged humans, higher
levels of Casp6 activity in the entorhinal cortex (ERC) and
Cornus Ammonis 1 (CA1) regions of the hippocampus
predict lower performance in episodic memory, the first
type of memory to be decreased in AD [3, 47]. Post-natal
expression of a self-activated form of human Casp6 in the
hippocampal CA1 region of mouse brains induces age-
related spatial and episodic memory impairment and is as-
sociated with early inflammation and neuronal loss [39].
Unlike the other two effector caspases, Casp3 and Casp7,
Casp6 does not induce cell death when activated [26, 33].
However, Casp6 causes axonal degeneration. Casp6
proteolytically cleaves cytoskeletal proteins crucial to
neuronal integrity and function, such as alpha-tubulin,
microtubule-associated protein Tau and post-synaptic
density proteins regulating the actin cytoskeleton of the
dendritic spines in synapses [29, 33, 56]. Casp6 is activated
and associated with axonal degeneration in nerve growth
factor-deprived mouse sensory neuron cultures, coordi-
nately with cellular apoptosis generated by effector Casp3
activation [45, 52, 53, 64]. In human primary neurons
transfected to overexpress wild type or Swedish and
London mutant amyloid precursor protein (APP), three
conditions associated with familial AD [11, 48], Casp6 is
activated in the absence of Casp3 activity and causes
axonal degeneration [37, 55]. This is consistent with the
absence of significant amounts of either active Casp3 or
Casp7 in AD brains that exhibit high amounts of active
Casp6 [37, 50, 57].
The early vulnerability of the ERC and CA1 to age-
related Casp6 activation is commensurate with early
NFT formation in pre-clinical Braak stages I and II of
AD [12]. In humans, neurons from the ERC project their
axons towards the CA1 region and receive input from
the olfactory bulb neurons. Therefore, degenerating
neurons of the olfactory bulb could cause degener-
ation of input neurons of the ERC, which require
synaptic signals for survival. Specifically, mitral and
tufted neurons of the olfactory bulb receive input
from neurons of the olfactory epithelium where the
olfactory nerves of the epithelium cross the cribriform
plate of the ethmoid bone. Mitral and tufted neurons
direct their axons to the olfactory tract and can form
clusters of axons called the AON in the olfactory
bulb and the olfactory tract, or project their axons to
the piriform cortex, the olfactory tubercle and the
lateral ERC [51].
The possibility that olfactory bulb degeneration is related
to hippocampal degeneration is supported by the fact that
odor identification impairment in aging is associated with
lower cognition [67]. Furthermore, impaired odor identifi-
cation predicts the progression of non-cognitively impaired
(NCI) to mild cognitively impaired (MCI) and of MCI to
AD, and is associated with decreased episodic and seman-
tic memory as well as decreased perceptual speed [68]. Im-
paired odor identification is also associated with NFT
pathology in the ERC [66]. Furthermore, the levels of Tau
and amyloid pathology in the olfactory bulb echoes the
presence and severity of AD brain pathologies found in
other regions, suggesting that brain biopsies of the ol-
factory bulb could be used for early diagnosis or to
monitor the effects of drug treatments [6]. Atrophy of
the olfactory bulb is detected in MCI and in AD and
correlate with lower mini mental state exam (MMSE)
scores [59–61]. The AON is the area most affected
by neuronal loss in AD [22]. Cholinergic neurons of
the olfactory system decrease by one third [35, 54]
and mitral cells are reduced significantly in AD olfac-
tory bulb [28, 58]. The AON is also the area where
NFT and senile plaques occur [16, 19, 30, 35, 41, 44, 46],
and the number of NFT is compatible with a diagnosis of
AD with an accuracy of 93.3% [34]. The NFT pathology of
the AON correlates with Braak stages, Lewy body path-
ology and the Apo E4 genotype [5, 23, 63].
Given the projection of olfactory tracts to the ERC, here,
we examined Casp6 activation in the olfactory bulb of
NCI, MCI and AD individuals. Casp6 activity was mainly
observed in the AON region of the olfactory bulb. Levels
of Casp6 activity correlated with PHF-1 NFT pathology in
the AON. Casp6 activity and PHF-1 NFT pathology in the
AON correlated with the levels of Casp6 activity in the
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ERC. In all AD dementia cases and a few MCI cases,
Casp6 activity in the AON region was higher than that
observed in the ERC. A similar trend was observed for
PHF-1. By contrast, levels of β-amyloid immunopositive
pathology were generally similar in the AON and the
ERC. Levels of AON Casp6 activity were associated with
lower cognition in four independent cognitive measures.
These results suggest that AON Casp6 activity could pre-
cede and induce Casp6-dependent ERC degeneration but
do not exclude the possibility that ERC degeneration
triggers AON degeneration. However, the results show an
association between AON and ERC degeneration.
Materials and methods
Human brain tissues
Olfactory bulb and hippocampal tissue sections were ob-
tained from the Religious Orders Study (ROS). The study
was approved by the Institutional Review Board of Rush
University Medical Center. All subjects signed informed
consent and an Anatomic Gift Act. The McGill University
Institutional Review Board approved the use of these hu-
man tissues in research. Details of the clinical and patho-
logic evaluation have been previously reported [9]. Yearly
clinical evaluations included a medical history, neuro-
logical and cognitive assessment and a clinical diagnosis.
Each case underwent MMSE to describe the cohort. Tests
of visuospatial ability, perceptual speed and episodic, se-
mantic and working memory evaluations yearly and these
were converted to Z scores (using the mean and S.D. at
baseline). A global cognitive score was developed by aver-
aging the 19 cognitive function tests used to assess the five
cognitive domains. Diagnostic classifications were pro-
vided by a clinician following the National Institute of
Neurological and Communicative Disorders and Stroke
and the AD and Related Disorders Association (NINCDS-
ADRDA) criteria, without consideration of the patho-
logical evaluation [42]. The diagnosis of AD dementia was
assigned to cases with a history of cognitive decline and
evidence of impairment of episodic memory and one
other cognitive domain. MCI referred to cases of cognitive
impairment without dementia. In the absence of dementia
or MCI, cases were assigned a NCI diagnosis. At autopsy,
brains underwent standard neuropathological evaluations,
including Braak Stage determination. Neuropathological
examination of the autopsied brains was done by a board-
certified neuropathologist according to a modified Con-
sortium to establish a registry for Alzheimer’s Disease
(CERAD) criteria, without access to clinical information
[8]. Brain tissue sections were stained with a Bielchowski
silver stain to reveal neuritic and diffuse plaques and NFT.
Braak stages were determined based on NFT severity and
distribution [31]. Other pathologies were examined. Only
2 AD from all subjects examined had typical hippocampal
sclerosis. Lewy body disease (alpha-synuclein), TDP-43,
atheriosclerosis, cerebral amyloid angiopathy, cerebral
artherosclerosis, gross chronic infarction and gross cere-
bral infarcts were present and mostly equivalent in the
brain of NCI, MCI and AD individual. Chronic microin-
farcts and micro infarctions were present only in NCI and
AD cases. Note that the clinical diagnosis was not always
in agreement with the neuropathological diagnosis [8] and
that our designation of AD, MCI and NCI in this paper is
based on the cognitive assessment.
A total of 34 cases comprising 18 NCI, 9 MCI and 7 AD
dementia were studied. Table 1 shows the demographic
and the clinical characteristics of the study group includ-
ing cognitive scores taken within a year of death and the
Braak stages of NFT pathology determined at autopsy.
The number of years of education and post-mortem inter-
val (PMI) were similar among the three groups. The AD
cases were slightly older and had lower cognitive scores
than the NCI and MCI groups.
Immunohistochemistry
Paraformaldehyde-fixed, paraffin-embedded 4 μm thick
olfactory bulb and hippocampal formation tissue sec-
tions were deparaffinized, hydrated and treated with
Table 1 Demographics and clinical characteristics of the study
groups
Characteristic NCI (n = 18) MCI (n = 9) AD (n = 7)
Age at death (yrs) 86.3 (6.4) 84.9 (6.8) 92.4 (4.7)
Male : Female 6 : 12 5 : 4 2 : 5
Education (yrs) 17.8 (3.2) 18.0 (1.8) 17.9 (2.1)
Post mortem interval,
median (IQR)
5.6 (5.3–6.3) 5.1 (4.5–7.3) 5.8 (4.5–13.3)
Apolipoprotein E ε4, n (%) 3 (16.7%) 2 (11.1%) 0
Mini mental state exam
(MMSE)
28.3 (1.8) 26.7 (1.9) 14.4 (8.3)
Cognitive test scores
Global Cognitive Scores 0.03 (0.4) −0.4 (0.5) −1.6 (0.8)
Episodic memory 0.4 (0.6) −0.3 (0.9) −2.2 (1.3)
Working memory −0.02 (0.5) −0.4 (0.8) −0.8 (0.4)
Semantic memory −0.1 (0.6) −0.3 (0.6) −1.3 (0.9)
Visuospatial activity −0.1 (0.6) −0.4 (0.9) −1.2 (0.3)
Perceptual Speed −0.3 (0.5) −0.9 (0.7) −1.6 (0.4)
Braak Stages, n (%)
0 1 (5.6%) 0 0
I 1 (5.6%) 1 (11.1%) 0
II 0 2 (22.2%) 1 (14.3%)
III 10 (55.6%) 3 (33.3%) 1 (14.3%)
IV 6 (33.3%) 3 (33.3%) 1 (14.3%)
V 0 0 4 (57.1%)
Data represent the mean and (SD). For Braak stage the number of cases and
the % in each group (NCI, MCI or AD)
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Tris-EDTA antigen retrieval buffer (10 mmol/LTris Base,
1 mmol/L ethylenediaminetetraacetic acid (EDTA),
0.05% Tween 20, pH 9) for 20 min at 97 °C in the Pascal
Dako Cytomation apparatus. The Dako Autostainer Plus
automated slide processor and the EnVision Flex system
(Dako, Burlington, ON, Canada) were used to perform
all the immunostaining. Brain cases with no pathology
were added as negative control, and previously identified
immunopositive AD hippocampus or cortical tissue sec-
tions added as positive controls for each immunostain-
ing. The following antisera or antibodies were used:
neoepitope antisera p20Casp6 10,630 antiserum (1/2000)
recognizing the processed active p20 subunit of Casp6
and 10,635 TauΔCasp6 (1/25,000) produced in our la-
boratory [27], F25276 antiserum (1/1000) raised against
Aβ1-40 peptide [36] and PHF-1 antibody (1/5000) against
phosphorylated Tau kindly provided by Dr Peter Davies
(Department of Neuroscience, Albert Einstein College of
Medicine, New York, NY). Slides were counterstained
with hematoxylin, dehydrated and coverslipped with
Permount mounting medium (Fisher Scientific, Ottawa,
ON, Canada).
The neuronal density of AON and ERC tissue was eval-
uated in three AD cases where both AON and ERC were
available, by counting the neurons within a defined area in
the counterstained hematoxylin/eosin Casp6 immuno-
stained tissue sections. Neurons were recognized accord-
ing to their morphological characteristics as defined [24].
At least 500 neuronal nuclei were counted per 3-4 differ-
ent regions of interest for each tissue section.
Cresyl violet staining (Nissl staining)
Olfactory bulb sections were deparaffinized with xylene, hy-
drated in descending series of ethanol concentrations and
treated with a 0.1% cresyl violet in water (Sigma-Aldrich, St
Louis, MO, USA) solution for 15 min followed by a few
seconds of differentiation in 95% ethanol. After staining,
the sections were dehydrated in absolute ethanol, treated
with xylene and coverslipped using Permount mounting
medium (Fisher Scientific, Ottawa, ON, Canada).
Quantitation of the immunopositive regions of the
olfactory bulb
Stained tissue sections were scanned digitally with the
MIRAX Scanner (Zeiss, Oberkochen, Germany). Con-
secutive cresyl violet stained olfactory bulb tissue sec-
tions were used to delineate the AON, and the
identification of the AON was determined by a neuro-
pathologist (SA) as described [51]. The AON was de-
fined as a group of large pyramidal neurons slightly
stained with cresyl violet. The Atlas of the Human Brain
was used as a reference to identify specific brain regions
[40]. Five regions of interest at least were photographed
at magnification × 20 with the MIRAX Viewer Program
(Zeiss, Oberkochen, Germany). Immunostaining density
was obtained with the ImageJ software (NIH, Bethesda,
MD, USA) and results were expressed as μm2 immuno-
positive staining/mm2 of tissue.
Statistical analyses
Descriptive statistics are reported for the variables of
interest. For categorical variables, we report counts and
percentages. For continuous variables whose distribution
of values showed evidence of being Normal, we report
mean and standard deviation (SD); otherwise we report
median and inter-quartile range (IQR). Spearman’s cor-
relations were run to determine monotonic relationship
between the different pathologies present in the AON or
the ERC and the relationship between the presence in
AON and ERC for each marker. The distributions of
values for active Casp6, TauΔCasp6, PHF-1 and Aβ be-
tween NCI, MCI and AD were compared with the
Kruskal-Wallis (KW) test. When warranted by a conclu-
sion of significant differences from the KW test, post-
hoc pairwise comparisons were performed with Dunn’s
multiple comparisons test [20, 21]. These comparisons
were done separately for the AON and the ERC. Mul-
tiple linear regressions were performed to investigate the
influence of pathological characteristics present in AON
or ERC (these analyses were done separately for the
AON and the ERC) on cognitive scores measured. The
models were adjusted for sex, age, PMI and years of edu-
cation. All statistical tests of hypothesis were two-sided
and carried out at the level of significance of 0.05. The
multiple linear regressions were done using the R
software (R Core Team (2016). R: A language and environ-
ment for statistical computing. R Foundation for Statistical
Computing, Vienna, Austria. URL https://www.R-project.
org/. All other statistical analyses were performed using
SAS, version 9.3 (SAS Institute, Cary, NC, USA).
Results
The AON is the region of the olfactory bulb most
immunopositive to active Casp6, TauΔCasp6, PHF-1 Tau
and Aβ
The AON area of the olfactory bulb whose neurites ex-
tend to the ERC (Fig. 1a) was chosen for quantification
of Casp6 activity since the AON represents the area that
is most strongly immunopositive to the neoepitope
antisera against the p20 active subunit of Casp6 and
TauΔCasp6, phosphorylated Tau PHF-1 antibodies and
anti-Aβ antiserum (Fig. 1b & c). Strong anti-active
Casp6 immunostaining was detected in neurons resem-
bling pre-NFT and mature NFT, and in neuropil threads,
as observed previously in AD cortex [27]. TauΔCasp6
immunoreactivity was detected in NFT-containing neu-
rons and neuropil threads of adjacent tissue sections,
and was more abundant than the immunoreactivity of
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the anti-active Casp6 as expected since this antiserum is
considerably stronger and Tau is more abundant in
neurons than the Casp6 enzyme. Casp6 activity was not
associated with apoptotic neuronal cell death based on the
normal appearance of the nuclei of immunopositive neu-
rons. PHF-1 immunostained NFT, although more sparsely
than the TauΔCasp6 antiserum. Conversely, PHF-1
immunostained neuropil threads more abundantly than
anti-active Casp6 and TauΔCasp6 neoepitope antisera.
Anti-Aβ immunostained β-amyloid deposits resembling
classical β-amyloid plaques and some smaller diffuse de-
posits. Together, these results show that both the proc-
essed form of active Casp6 and TauΔCasp6, that define
Casp6 activity, co-exist with classical AD pathology in the
AON of the olfactory bulb.
Levels of active Casp6 correlate with TauΔCasp6 and
PHF-1, but not with Aβ, in the AON of the olfactory bulb
Spearman’s correlation showed a strong positive relation-
ship between the anti-active Casp6 and the TauΔCasp6 in
Fig. 1 Casp6, Tau and Aβ pathologies are present in the AON of Olfactory Bulb from ROS study subjects. a Schematic diagram of the human
olfactory bulb and its cell composition (adapted from Saiz-Sanchez D. et al., [49]). b Representative image of horizontal section of human olfactory
bulb (OB) (bar scale = 1000 μm) stained for active Casp6 with higher magnification showing delineation of the AON (bar scale = 100 μm). c
Representative images of negative and positive immunohistochemical staining of active Casp6, TauΔCasp6, PHF-1 and Aβ in the AON (bar = 50 μm).
The square in the immunopositive AON panel has been magnified 4.5 fold
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the AON of the olfactory bulb (rs = 0.61, n = 21, p = 0.003)
(Fig. 2a). Both the anti-active Casp6 and the TauΔCasp6
immunostaining showed a strong positive relationship
with PHF-1 immunostaining (rs = 0.63, n = 20, p = 0.003
and rs = 0.69, n = 20, p = 0.001, respectively) indicating, as
observed previously in hippocampus [47], an association
between Tau NFT pathology and Casp6 activity. By
contrast, neither the anti-active Casp6 nor TauΔCasp6
immunostaining showed a relationship with Aβ im-
munostaining (rs = 0.44, n = 19, p = 0.06 and rs = 0.18,
n = 22, p = 0.47, respectively). The level of PHF-1
showed a weak positive relationship with Aβ immu-
nostaining in the AON (rs = 0.47, n = 22, p = 0.03).
Spearman’s correlation also showed a strong positive re-
lationship between anti-active Casp6 and TauΔCasp6
immunopositivity in the ERC (rs = 0.69, n = 21, p = 0.001)
(Fig. 2b). As observed in the AON, both the anti-active
Casp6 and the TauΔCasp6 immunostaining showed a
strong positive relationship with the PHF-1 immuno-
staining in the ERC (rs = 0.69, n = 18, p = 0.001 and rs =
0.85, n = 19, p < 0.0001, respectively). Active Casp6 did not
show a relationship with Aβ immunostaining in the ERC
(rs = 0.19, n = 19, p = 0.42), but TauΔCasp6 did (rs =
0.52, n = 21, p = 0.02). Levels of Aβ immunostaining
showed a strong positive relationship with PHF-1 immu-
nostaining only in the ERC (rs = 0.68, n = 19, p = 0.002).
Together, these results indicate that Casp6 activity is
strongly associated with NFT pathology, but not with
Aβ pathology, in the AON of the olfactory bulb and
in the ERC.
AON active Casp6 and ERC TauΔCasp6 increase with AD
progression
Table 2 shows descriptive statistics for pathological
markers by brain region and clinical diagnosis. A KW
test showed statistical significant differences in the levels of
active Casp6 in the AON (χ2 (2 degrees of freedom) = 6.05,
p = 0.04). A post-hoc Dunn’s test, showed a difference be-
tween AD dementia and NCI, as well as between AD de-
mentia and MCI. By contrast, although TauΔCasp6 in the
AON showed higher amounts in AD dementia as com-
pared to NCI and MCI, the KW test showed that there
were no statistically significant differences. This may be ex-
plained by the fact that the variability in TauΔCasp6 values,
as measured by the IQR, is greater within AD dementia,
NCI and MCI. Similarly for PHF-1 and Aβ, there were no
statistically significant differences between the clinical diag-
nostic groups.
Fig. 2 Active Casp6 and TauΔCasp6 staining shows a positive monotonic relationship with PHF-1 staining in AON and ERC. Scatterplots and Spearman’s
correlation (rs) between the active Casp6, TauΔCasp6, PHF-1 and Aβ immunostaining (μm
2 staining/mm2 of tissue) in the AON (a) and in the ERC (b)
Foveau et al. Acta Neuropathologica Communications  (2016) 4:127 Page 6 of 13
In the ERC, there were no statistically significant dif-
ferences in the levels of active Casp6 between NCI, MCI
and AD brains. However, differences in levels of ERC
TauΔCasp6 were observed (KW test, χ2 (2 df ) = 8.37,
p = 0.01). A post-hoc Dunn’s test, showed a difference
between AD and NCI. Similarly, statistically signifi-
cant differences in the levels of ERC PHF-1 (KW test,
χ2 (2 df ) = 7.13, p = 0.02) and Aβ levels (KW test, χ2
(2) = 8.32, p = 0.01) were obtained and post-hoc
Dunn’s test confirmed a difference between AD and
NCI, and between AD and MCI. Together, these re-
sults indicate higher levels of active Casp6, but not
TauΔCasp6, PHF-1 or Aβ, in the AD AON than in
the NCI or MCI AON. By contrast, levels of active
Casp6 are not different in NCI, MCI or AD ERC,
TauΔCasp6 is increased in AD ERC relative to NCI
ERC levels, but PHF-1 and Aβ levels are increased in
AD ERC compared to both NCI and MCI ERC.
Levels of Casp6 activity in the AON correlate with the
levels of Casp6 activity and PHF-1 positive NFT in the ERC
It is expected that if degeneration in the ERC occurs
because of the degeneration of input neurons in the
AON, then Casp6 activity in the AON should show a re-
lationship with that of the ERC. Spearman’s correlation
showed that levels of anti-active Casp6 in the AON did
not have a significant relationship with those in the ERC
(rs = 0.15, n = 14, p = 0.60) (Fig. 3a). However, levels of
TauΔCasp6 immunoreactivity in the AON were associ-
ated positively with those in the ERC (rs = 0.70, n = 14, p
= 0.01) (Fig. 3b). Since cytosolic caspase enzyme levels
are lower than the cytoskeletal Tau protein and because
Casp6 undergoes rapid turnover by the proteasome [62],
we consider TauΔCasp6 to be a stronger indicator of
Casp6 activity than active Casp6. Furthermore, PHF-1
immunostaining in AON were associated positively with
that of the ERC (rs = 0.75, n = 14, p = 0.002) (Fig. 3c). By
contrast, Aβ levels in the AON did not show a relation-
ship with those in the ERC (rs = 0.41, n = 15, p = 0.12)
(Fig. 3d). These results indicate that degeneration in
the AON parallels that of the ERC but does not give
any information as to whether degeneration in the
AON preceded that in the ERC. To assess this possi-
bility, we compared immunopositive levels where
staining were obtained in both the AON and ERC of
the same case (Fig. 4). All 3 AD dementia cases and
one MCI case showed higher active Casp6 in the
AON than in the ERC (Fig. 4a). Two out of 3 AD de-
mentia cases and 2 MCI cases showed higher TauΔ-
Casp6 in the AON than in the ERC (Fig. 4b).
Similarly, PHF-1 levels in AON were higher in AD
and 2 MCI cases (Fig. 4c). By contrast, Aβ was higher
in AON in only one AD case, other cases showed
similar levels.
Table 2 AON and ERC immunostaining levels in NCI, MCI and AD
Region of interest Clinical Diagnosis Active Casp6 TauΔCasp6 PHF-1 Aβ
AON NCI Median 837.7 472.9 3655.9 403.3
IQR 289.0–1481.8 263.0–4182.6 1248.2–23248.5 109.9–658.2
n 11 11 11 10
MCI Median 226.1 980.7 7494.4 452.9
IQR 118.1–2705.2 458.0–9493.4 651.1–67082.5 136.3–2993.1
n 6 6 7 7
AD Median 23982.4 20400.0 75146.7 27355.0
IQR 11445.0–26221.2 3087.2–54521.9 41473.2–151857.4 1222.9–55633.7
n 4 4 5 5
ERC NCI Median 69.7 29.3 4138.2 940.7
IQR 53.8–518.3 10.8–1138.3 615.9–16672.1 106.5–3406.6
n 8 9 9 9
MCI Median 662.4 1035.8 15562.1 96.1
IQR 14.4–1639.4 246.8–3901.1 9394.8–42729.6 54.2–4787.4
n 7 7 7 7
AD Median 1022.1 7859.5 56051.4 14342.6
IQR 497.2–1453.1 3181.4–18251.4 53590.7–70360.4 11159.6–24689.1
n 4 5 3 5
Data represent the median (μm2 staining/μm2 tissue) and the Inter-Quartile Range (25% percentile-75% percentile). n indicates the number of cases studied with
each immunostaining in this region of interest. Comparisons of distributions for pathological markers by clinical diagnosis were done separately in the AON and
in the ERC using the Kruskal-Wallis test, followed by a Dunn’s post-hoc test where warranted (results and p values are reported in the text)
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Fig. 3 AON TauΔCasp6 and PHF-1 staining shows a positive monotonic relationship with ERC staining. Scatterplots and Spearman’s correlations
(rs) between the active Casp6 (a), TauΔCasp6 (b), PHF-1 (c) and Aβ (d) immunostaining (μm2 staining/mm2 of tissue) in the AON versus the ERC
Fig. 4 Casp6 and Tau pathologies are more abundant in AON than in the ERC for AD cases. Active Casp6 (a), TauΔCasp6 (b), PHF-1 (c) and Aβ
(d) immunostaining values (μm2 staining/mm2 of tissue) in the AON and ERC for 5 NCI, 3 MCI and 3 AD cases where both the AON and ERC were
stained from the same individual case
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Together, these results suggest that either the AON
is more susceptible to Casp6 activation and PHF-1
immunopositive AD pathology than the ERC or that
the AON pathology precedes the ERC pathology and
this result in a greater accumulation of Casp6 activity
and PHF-1 pathology.
Higher levels of active Casp6 in the AON correlate with
lower cognitive performance
To investigate the association between the pathologies
of the AON or ERC and the cognitive performance of
individuals, we performed separate regression analyses
for five cognitive domains assessed within a year of
death. Analyses were done separately for the AON and
the ERC. In each regression, we adjusted for sex, age,
PMI and years of education. Spearman’s correlation
results discussed above showed that active Casp6, TauΔ-
Casp6 and PHF-1 immunostaining were highly associ-
ated with one another. Multicollinearity of these three
factors was confirmed by their high values of the vari-
ance inflation factor found in a preliminary for-diagnosis
multiple regression model. To adjust for this multicolli-
nearity, we used a ridge regression approach, which al-
lows for the inclusion of these factors in the same
model. The value of the ridge parameter λ was chosen
as the one for which the coefficients were relatively
stable from the ridge traces. The values selected were λ
= 20 and λ = 100 for AON and ERC, respectively. Fur-
thermore, due to the small sample sizes, p values for the
regression coefficients were computed using a
Table 3 Ridge regression coefficients of cognitive performance scores from AON and ERC pathologies
AON (n = 19) ERC (n = 18)
Predicting cognition Marker Coefficient p value Marker Coefficient p value
GCS Active Casp6 −0.18 0.01 Active Casp6 −0.02 0.40
TauΔCasp6 −0.08 0.29 TauΔCasp6 −0.05 0.06
PHF-1 −0.06 0.33 PHF-1 −0.03 0.27
Aβ −0.18 0.04 Aβ −0.03 0.27
MMSE Active Casp6 −1.97 0.001 Active Casp6 −0.29 0.23
TauΔCasp6 −1.36 0.05 TauΔCasp6 −0.72 0.01
PHF-1 −0.92 0.06 PHF-1 −0.41 0.04
Aβ −0.90 0.21 Aβ −0.30 0.14
Episodic Memory Active Casp6 −0.31 0.01 Active Casp6 −0.02 0.67
TauΔCasp6 −0.13 0.32 TauΔCasp6 −0.07 0.07
PHF-1 −0.14 0.17 PHF-1 −0.05 0.24
Aβ −0.28 0.05 Aβ −0.05 0.27
Working memory Active Casp6 −0.06 0.26 Active Casp6 −0.02 0.21
TauΔCasp6 −0.03 0.59 TauΔCasp6 −0.01 0.64
PHF-1 −0.004 0.93 PHF-1 −0.004 0.81
Aβ −0.09 0.16 Aβ 0.001 0.95
Semantic memory Active Casp6 −0.15 0.03 Active Casp6 −0.01 0.69
TauΔCasp6 −0.11 0.14 TauΔCasp6 −0.05 0.05
PHF-1 −0.07 0.25 PHF-1 −0.02 0.55
Aβ −0.16 0.06 Aβ −0.03 0.28
VSA Active Casp6 −0.09 0.12 Active Casp6 −0.01 0.62
TauΔCasp6 −0.01 0.91 TauΔCasp6 −0.01 0.84
PHF-1 0.02 0.72 PHF-1 −0.01 0.57
Aβ −0.06 0.41 Aβ −0.03 0.21
PS Active Casp6 −0.08 0.23 Active Casp6 −0.05 0.05
TauΔCasp6 −0.07 0.32 TauΔCasp6 −0.05 0.04
PHF-1 −0.02 0.71 PHF-1 −0.02 0.29
Aβ −0.04 0.64 Aβ −0.02 0.31
Data represent the ridge regression analysis of the different markers in the AON and the ERC and the cognitive scores. Model adjusted for sex, age, PMI and years
of education, in bold p values less or equal to 0.05
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permutation method with 10,000 permutations [17]. All
ridge regressions and permutation tests were performed
using the package MASS in R [65].
Higher levels of active Casp6 in the AON were associ-
ated with lower global cognitive, MMSE, episodic and se-
mantic memory scores (Table 3). TauΔCasp6 and Aβ
levels in the AON were marginally negatively associated
with the MMSE score and GCS, respectively. By contrast,
PHF-1 levels in the AON were not associated with any of
the cognitive measures. In the ERC, active Casp6 and
TauΔCasp6 levels were marginally negatively associated
with perceptual speed, and episodic memory or perceptual
speed, respectively. TauΔCasp6 levels were however nega-
tively associated with MMSE scores, a feature observed
also for PHF-1, although the association was weak. Aβ
levels did not associate with any of the cognitive measures.
These results indicate that AON active Casp6 levels are
associated with cognitive decline, and interestingly, the as-
sociation is with episodic and semantic memory, two types
of memory function initially altered in AD.
Discussion
In this study, the levels of Casp6 activity were assessed
in the olfactory bulb of NCI, MCI and AD dementia in-
dividuals to determine if previously observed Casp6 ac-
tivity in the ERC was associated with degeneration in
the olfactory bulb since olfactory bulb neurons project
their axons to the ERC. The results of the study revealed
that (1) Casp6 activity is highest in and mostly restricted
to the AON of the olfactory bulb and co-exists with Tau,
but not Aβ, AD pathology, (2) Casp6 activity increases
in the AON with the progression of disease and appears
to be higher than that of Casp6 activity in the ERC, and
(3) active Casp6 levels in the AON are negatively associ-
ated with cognitive performance.
The co-existence of Casp6 activity with Tau pathology
in the AON of the olfactory bulb is consistent with our
previous observations of an intimate relationship be-
tween Casp6 activity and PHF-1 Tau pathology in the
ERC and CA1 regions of the hippocampus [47]. The fact
that both Tau and Casp6 are localized in the neuronal
cytosol and are involved in axonal degeneration suggests
that they could both be part of a neurodegeneration path-
way in AD neurons [18, 45, 55]. Casp6 cleavage of Tau at
amino acid 402 [27] may impact Tau’s polymerization, as
observed for cleaved Tau at amino acids 391 and 421
[1, 10]. Cleavage of Tau may also alter Tau’s function in
the stabilization of microtubules, in a manner similar to
the phosphorylation of Tau at amino acid 396 [13].
Whether NFT formation and Casp6 activity occur as par-
allel pathways of degeneration or as part of the same path-
way remains to be determined, and will be an important
question to resolve eventually as the answer would have a
significant implication in the development of treatments
against neurodegeneration in AD.
In contrast to its association with NFT pathology,
Casp6 activity in the AON is not associated with Aβ
extracellular deposits. The lack of association between
Casp6 activity and Aβ is consistent with our previous
observations in the hippocampus [3, 27, 47]. Our results
differ from several reports indicating β-amyloid toxicity
associated with caspase activation [7, 14, 15]. Neverthe-
less, our analyses cannot exclude the possibility of toxic
Aβ oligomers triggering neuronal Casp6 activation. It is
also important to consider that Aβ production can be a
consequence of Casp6 activation in primary cultures of
human CNS neurons [32, 36, 38], a fact that would be
consistent with Casp6 activity preceding Aβ over-
production and deposition as extracellular plaques.
This study shows that Casp6 activity in the AON
could be added as an additional biomarker of neurode-
generation associated with AD. First, the AON active
Casp6 levels were significantly higher in AD compared
to AON NCI or MCI, indicating increased levels of en-
zyme with progression of disease. A similar trend was
observed with TauΔCasp6 but did not reach statistical
significance because of the large variability amongst
samples. Second, the levels of TauΔCasp6 in the AON
were positively and strongly associated with the levels of
TauΔCasp6 in the ERC. Similar results were observed
for PHF-1 pathology. Third, the higher levels of Casp6
activity, determined by both the presence of active
Casp6 and TauΔCasp6, and PHF-1 Tau, in the AON
than in the ERC of individual MCI and AD cases suggest
that degeneration in the AON could precede degener-
ation in the ERC. However, our approach cannot exclude
that ERC degeneration leads to AON degeneration or
that the two pathologies occur concomitantly. More in-
tensive studies will be required to determine which of
these three possibilities explains the relationship be-
tween AON and ERC degeneration. The number of
available cases evaluated limited our study. Furthermore,
a longitudinal study would be required to determine if
pathology in one area of the brain precedes another.
This longitudinal study would require the ability to ob-
serve the degeneration in live patients. This is likely to
soon become possible with the evolution of PET ligands
against tangles and Aβ, but is not yet possible for Casp6
activity. Furthermore, as proposed by Attems [4–6], ol-
factory biopsies could be done to assess the diagnostic
potential of the olfactory bulb, and to evaluate the effi-
ciency of treatments against AD.
This study shows an association between higher levels
of AON active Casp6 and lower memory performance. In-
deed, higher levels of Casp6 associate with lower global
cognitive, MMSE and episodic and semantic memory,
scores. These results are consistent with the association of
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impaired odor identification and lower global cognition
and a more rapid rate of episodic and semantic memory
decline in MCI [68]. The fact that episodic and semantic
memory impairment occurs before AD dementia [43]
suggests the involvement of Casp6 activity at a very early
stage of the disease. In other studies, an association be-
tween olfactory bulb and tract atrophy and MMSE scores
was observed [60, 61]. Given the role of Casp6 in axonal
degeneration [45, 55], it would be of interest to determine
eventually if Casp6 activity may be responsible for the at-
rophy of the olfactory bulb and tract. Surprisingly, AON
TauΔCasp6 showed only a marginal association with a de-
cline in MMSE score and no association with the other
cognitive measures. Similarly, no association was observed
between AON PHF-1 levels and cognitive measures.
These results suggest that the presence of Tau pathology
in the AON is not associated with cognitive performance.
Similarly, the AON levels of Aβ associated very weakly
with lower GCS and not with any of the other measures
of cognition. However, with larger numbers, significance
may be achieved. For example, an association between ol-
factory Tau pathology and clinical dementia in AD and
MCI subjects has been reported [4, 5].
In the ERC, TauΔCasp6 and PHF-1 levels associated
negatively with the MMSE score. Active Casp6 and
TauΔCasp6 levels both associated negatively but very
weakly with perceptual speed performance. Similarly, a
very weak association between TauΔCasp6 and semantic
memory was also observed. Aβ levels did not associate
with any of the cognitive measures. Previously, we did
not observe an association between cognition and Casp6
activity in the ERC when combining NCI, MCI and AD
groups, but detected a significant association between
episodic and semantic memory and Casp6 activity in the
NCI subjects ERC [3, 47]. Larger numbers in each sub-
group will be required for a solid conclusion to be
drawn. Since the focus of this study was the olfactory
bulb, we did not pursue the study in the ERC.
Conclusions
In conclusion, these data support the possibility that the
Casp6 activity in the AON of the olfactory bulb reflects
degeneration in the ERC and suggest that Casp6 activity
in the olfactory bulb could represent degeneration asso-
ciated with cognitive decline and early AD. Furthermore,
Casp6 in the AON could be used as an early marker to
detect the initiation of pathways of degeneration in AD.
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